Cargando…

The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients

BACKGROUND: To evaluate atherosclerotic changes in carotid arteries (CCA) in uremic patients before and after 18 months of continuous ambulatory peritoneal dialysis (CAPD) treatment, and to evaluate the impact of dyslipidemia and CAPD treatment on vascular remodeling. MATERIALS AND METHODS: We condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebić, Damir, Begić, Edin, Aziri, Buena, Džubur, Alen, Gogić, Ena, Durak-Nalbantić, Azra, Hamzić-Mehmedbašić, Aida, Hasanspahić, Senad, Granov, Nermir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331554/
https://www.ncbi.nlm.nih.gov/pubmed/37434937
http://dx.doi.org/10.4103/abr.abr_1_23
_version_ 1785070278982762496
author Rebić, Damir
Begić, Edin
Aziri, Buena
Džubur, Alen
Gogić, Ena
Durak-Nalbantić, Azra
Hamzić-Mehmedbašić, Aida
Hasanspahić, Senad
Granov, Nermir
author_facet Rebić, Damir
Begić, Edin
Aziri, Buena
Džubur, Alen
Gogić, Ena
Durak-Nalbantić, Azra
Hamzić-Mehmedbašić, Aida
Hasanspahić, Senad
Granov, Nermir
author_sort Rebić, Damir
collection PubMed
description BACKGROUND: To evaluate atherosclerotic changes in carotid arteries (CCA) in uremic patients before and after 18 months of continuous ambulatory peritoneal dialysis (CAPD) treatment, and to evaluate the impact of dyslipidemia and CAPD treatment on vascular remodeling. MATERIALS AND METHODS: We conducted a longitudinal, prospective study during 2020 and 2021 at the Clinic for Nephrology, Clinical Center University of Sarajevo. Patients with end-stage renal disease were included and were followed during 18 months of CAPD treatment. All patients were treated using commercially prepared biocompatible balanced dialysis solutions. Carotid intima-media thickness (IMT) and atherosclerotic plaques on the common carotid artery (CCA) were measured by echotomography. RESULTS: A total of 50 patients were included and were followed during 18 months of CAPD treatment. Lipid values in the serum of patients with CAPD were significantly lower after 18 months of CAPD treatment compared to the values before treatment, while the value of high-density lipoprotein (HDL) was significantly increased after 18 months of CAPD treatment. The values of IMT and the diameter of the CCA compared to the basal values were significantly lower (P < 0.001). CONCLUSION: We demonstrated significantly lower lipid values and higher HDL levels following CAPD treatment. Correct selection of the targeted pharmacological intervention can substantially impact the regression of vascular changes in patients on peritoneal dialysis.
format Online
Article
Text
id pubmed-10331554
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103315542023-07-11 The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients Rebić, Damir Begić, Edin Aziri, Buena Džubur, Alen Gogić, Ena Durak-Nalbantić, Azra Hamzić-Mehmedbašić, Aida Hasanspahić, Senad Granov, Nermir Adv Biomed Res Original Article BACKGROUND: To evaluate atherosclerotic changes in carotid arteries (CCA) in uremic patients before and after 18 months of continuous ambulatory peritoneal dialysis (CAPD) treatment, and to evaluate the impact of dyslipidemia and CAPD treatment on vascular remodeling. MATERIALS AND METHODS: We conducted a longitudinal, prospective study during 2020 and 2021 at the Clinic for Nephrology, Clinical Center University of Sarajevo. Patients with end-stage renal disease were included and were followed during 18 months of CAPD treatment. All patients were treated using commercially prepared biocompatible balanced dialysis solutions. Carotid intima-media thickness (IMT) and atherosclerotic plaques on the common carotid artery (CCA) were measured by echotomography. RESULTS: A total of 50 patients were included and were followed during 18 months of CAPD treatment. Lipid values in the serum of patients with CAPD were significantly lower after 18 months of CAPD treatment compared to the values before treatment, while the value of high-density lipoprotein (HDL) was significantly increased after 18 months of CAPD treatment. The values of IMT and the diameter of the CCA compared to the basal values were significantly lower (P < 0.001). CONCLUSION: We demonstrated significantly lower lipid values and higher HDL levels following CAPD treatment. Correct selection of the targeted pharmacological intervention can substantially impact the regression of vascular changes in patients on peritoneal dialysis. Wolters Kluwer - Medknow 2023-05-19 /pmc/articles/PMC10331554/ /pubmed/37434937 http://dx.doi.org/10.4103/abr.abr_1_23 Text en Copyright: © 2023 Advanced Biomedical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Rebić, Damir
Begić, Edin
Aziri, Buena
Džubur, Alen
Gogić, Ena
Durak-Nalbantić, Azra
Hamzić-Mehmedbašić, Aida
Hasanspahić, Senad
Granov, Nermir
The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
title The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
title_full The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
title_fullStr The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
title_full_unstemmed The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
title_short The Role of Dyslipidemia in Atherogenesis in Peritoneal Dialysis Patients
title_sort role of dyslipidemia in atherogenesis in peritoneal dialysis patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331554/
https://www.ncbi.nlm.nih.gov/pubmed/37434937
http://dx.doi.org/10.4103/abr.abr_1_23
work_keys_str_mv AT rebicdamir theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT begicedin theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT aziribuena theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT dzuburalen theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT gogicena theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT duraknalbanticazra theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT hamzicmehmedbasicaida theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT hasanspahicsenad theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT granovnermir theroleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT rebicdamir roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT begicedin roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT aziribuena roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT dzuburalen roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT gogicena roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT duraknalbanticazra roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT hamzicmehmedbasicaida roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT hasanspahicsenad roleofdyslipidemiainatherogenesisinperitonealdialysispatients
AT granovnermir roleofdyslipidemiainatherogenesisinperitonealdialysispatients